EUVIMEDEUVIMED entdecken
Crossref

Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer

Qiyu Zhu iD, Ling Wang iD, Junru Chen, Xiuya Zhou, Zehua Tan, Jingjing Guo, Haoyang Liu, Ling Nie, Ni Chen, Pengfei Shen, Zhenhua Liu, Hao Zeng und 1 weitere

International Journal of Cancer · 03.11.2026

DOI: 10.1002/ijc.70806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 03.11.2026. Verfasst von Qiyu Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, National Natural Science Foundation of China, Beijing Bethune Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intraductal carcinoma of the prostate (IDC‐P) has been associated with increased homologous recombination deficiency (HRD). We evaluated the association between IDC‐P and the efficacy of olaparib plus novel hormonal therapy (NHT) in metastatic castration‐resistant prostate cancer (mCRPC) after progression on prior NHT. A total of 64 consecutive patients were analyzed, including 33 with IDC‐P and 31 with prostate adenocarcinoma (PAC). An external validation cohort of 36 patients from two additional centers was also included. Primary outcomes were progression‐free survival (PFS), while treatment‐change free survival (TFS), prostate‐specific antigen response, overall survival, and adverse events were additionally assessed. After a median follow‐up of 35.0 months, IDC‐P was associated with longer PFS and TFS than PAC (PFS, 6.2 vs. 3.0 months; TFS, 10.0 vs. 6.3 months; both p < 0.01). This association remained significant in patients with BRCA1/2 mutations and after multivariable adjustment for BRCA1/2 mutation status. In the validation cohort, IDC‐P status was associated with longer PFS (6.1 vs. 3.1 months, p = 0.02). In an independent cohort of 187 patients with prostate cancer, IDC‐P was associated with higher HRD scores than PAC in the BRCA1/2‐mutated subgroup, with a nonsignificant trend in the BRCA1/2‐wild‐type subgroup, suggesting a possible biological context for the observed outcome association. These findings suggest that IDC‐P may serve as a practical pathological biomarker associated with improved outcomes following PARP inhibitor‐based therapy in mCRPC, although further large‐scale prospective validation is warranted.

Schlagwörter

Stichwörter der Autor:innen

BRCAintraductal carcinoma of the prostatemetastatic castration‐resistant prostate cancernovel hormonal therapyolaparib

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Urology, Institute of Urology, West China Tianfu Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Qiyu Zhu, Ling Wang

Förderung

  • West China Hospital, Sichuan University
  • National Natural Science Foundation of China
  • Beijing Bethune Charitable Foundation
  • Science and Technology Department of Sichuan Province
  • Special Research Fund for Radionuclide Diagnosis and Therapy of Prostate Cancer
  • China National Nuclear Corporation

Zitieren

APA

Zhu, Q., Wang, L., Chen, J., Zhou, X., Tan, Z., Guo, J., Liu, H., Nie, L., Chen, N., Shen, P., Liu, Z., Zeng, H., & Zhao, J. (2026). Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70806

Vancouver

Zhu Q, Wang L, Chen J, Zhou X, Tan Z, Guo J, et al. Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70806

BibTeX
@article{Zhu2026,
  author = {Zhu, Qiyu and Wang, Ling and Chen, Junru and Zhou, Xiuya and Tan, Zehua and Guo, Jingjing and Liu, Haoyang and Nie, Ling and Chen, Ni and Shen, Pengfei and Liu, Zhenhua and Zeng, Hao and Zhao, Jinge},
  title = {Intraductal Carcinoma of the Prostate Is Associated With Improved Efficacy of Olaparib Combined With Novel Hormonal Therapy in Metastatic Castration‐Resistant Prostate Cancer},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70806}
}
Kostenlos starten →